Downregulation of AMPK Accompanies Leucine- and Glucose-Induced Increases in Protein Synthesis and Insulin Resistance in Rat Skeletal Muscle by Saha, Asish K. et al.
Downregulation of AMPK Accompanies Leucine- and
Glucose-Induced Increases in Protein Synthesis and
Insulin Resistance in Rat Skeletal Muscle
Asish K. Saha,
1 X. Julia Xu,
1 Ebony Lawson,
1 Rosangela Deoliveira,
1 Amanda E. Brandon,
2
Edward W. Kraegen,
2 and Neil B. Ruderman
1
OBJECTIVE—Branched-chain amino acids, such as leucine and
glucose, stimulate protein synthesis and increase the phosphor-
ylation and activity of the mammalian target of rapamycin
(mTOR) and its downstream target p70S6 kinase (p70S6K). We
examined in skeletal muscle whether the effects of leucine and
glucose on these parameters and on insulin resistance are
mediated by the fuel-sensing enzyme AMP-activated protein
kinase (AMPK).
RESEARCH DESIGN AND METHODS—Rat extensor digito-
rum longus (EDL) muscle was incubated with different concen-
trations of leucine and glucose with or without AMPK activators.
Muscle obtained from glucose-infused rats was also used as a
model.
RESULTS—In the EDL, incubation with 100 or 200 mol/l
leucine versus no added leucine suppressed the activity of the 2
isoform of AMPK by 50 and 70%, respectively, and caused
concentration-dependent increases in protein synthesis and
mTOR and p70S6K phosphorylation. Very similar changes were
observed in EDL incubated with 5.5 or 25 mmol/l versus no added
glucose and in muscle of rats infused with glucose in vivo.
Incubation of the EDL with the higher concentrations of both
leucine and glucose also caused insulin resistance, reﬂected by a
decrease in insulin-stimulated Akt phosphorylation. Coincuba-
tion with the AMPK activators AICAR and -lipoic acid substan-
tially prevented all of those changes and increased the
phosphorylation of speciﬁc sites of mTOR inhibitors raptor and
tuberous sclerosis complex 2 (TSC2). In contrast, decreases in
AMPK activity induced by leucine and glucose were not associ-
ated with a decrease in raptor or TSC2 phosphorylation.
CONCLUSIONS—The results indicate that both leucine and
glucose modulate protein synthesis and mTOR/p70S6 and insulin
signaling in skeletal muscle by a common mechanism. They also
suggest that the effects of both molecules are associated with a
decrease in AMPK activity and that AMPK activation prevents
them. Diabetes 59:2426–2434, 2010
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MP-activated protein kinase (AMPK) is a fuel-
sensing enzyme that has classically been de-
ﬁned in terms of its role in restoring ATP levels
in energy-depleted cells. In skeletal muscle,
AMPK is typically activated by such factors as glucose
deprivation and contraction (exercise) (1,2). The activated
AMPK in turn enhances processes that generate ATP, such
as fatty acid oxidation and glucose transport, and down-
regulates others that consume ATP and can be diminished
temporarily without jeopardizing the cell (e.g., protein and
lipid synthesis). Much less studied is the notion that a
decrease in AMPK below baseline values may also be a
physiologically or pathophysiologically relevant event. In
keeping with such a possibility, decreased AMPK activity
has been observed in tissues of many obese insulin-
resistant rodents (3) and in liver (4,5) and adipose tissue
(6) of rats starved for 48 h when they are refed. One
consequence of decreased AMPK activity could be in-
creases in mammalian target of rapamycin (mTOR)/p70S6
kinase (p70S6K) signaling and protein synthesis because
both are decreased by AMPK activation (7).
In the present study, we assessed whether fuel-induced
increases in protein synthesis, mTOR/p70S6K signaling,
and insulin resistance in skeletal muscle are mediated by
decreases in AMPK activity. Toward this end, rat extensor
digitorum longus (EDL) muscles were incubated for dif-
ferent time periods with various concentrations of leucine
or glucose and the above parameters were assessed. The
results indicate that elevated concentrations of leucine
and glucose decrease AMPK activity, increase protein
synthesis and mTOR/p70S6 phosphorylation, and cause
insulin resistance and that activation of AMPK by pharma-
cological agents prevents these events from occurring.
Finally, the data suggest that the decrease in AMPK
activity caused by both leucine and glucose is not medi-
ated by changes in the AMP-to-ATP ratio but is associated
with an increase in the lactate/pyruvate ratio.
RESEARCH DESIGN AND METHODS
5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) was purchased
from Toronto Research Chemicals (Toronto, ON, Canada). Compound C, a
selective AMPK inhibitor, was purchased from Calbiochem (San Diego, CA).
[-
32P] ATP was purchased from NEN (Boston, MA) and protein A/G plus
conjugate from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies for
phosphorylated AMPK (P-AMPK) (Thr 172), total AMPK, phosphorylated
mTOR (P-mTOR) (Ser 2448), phosphorylated p70S6K (P-p70S6K) (Thr 389),
and phosphorylated 4EBP (P-4EBP) (Thr 70) were obtained from Cell
Signaling (Danvers, MA) and for phosphorylated acetyl CoA carboxylase
(P-ACC) (Ser 79) from Upstate Biotechnologies (Charlottesville, VA). Phos-
phorylated tuberous sclerosis complex 2 (TSC2) (Ser 1387) was purchased
from LifeSpan Biosciences (Seattle, WA). Total and phosphorylated raptor
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Regulator T1) (H-300) were from Santa Cruz Biotechnology. SAMS peptide
and polyclonal antibodies that immunoprecipitate the 1 and 2 catalytic
subunit of AMPK were obtained from QCB Biotechnology (Hopkinton, MA).
All other chemicals were purchased from either Sigma-Aldrich or Fisher.
Protocols for animal use were reviewed and approved by the Institutional
Animal Care and Use Committee of Boston University Medical Center and
were in accordance with National Institutes of Health guidelines. Male
Sprague-Dawley rats weighing 55–65 g were purchased from Charles River
Breeding Laboratories (Wilmington, MA). They were maintained on a 12:12-h
light-dark cycle in a temperature-controlled (19–21°C) room and were fed
standard Purina rat chow and water ad libitum. Food was withdrawn 16–20 h
before the initiation of experimental protocols. Muscles were removed from
rats anesthetized with pentobarbital (6 mg/100 g body wt).
Muscle incubation. After removal from the rat EDL muscles, the samples
were ﬁrst equilibrated for 20 min at 37°C in oxygenated Krebs-Henseleit
solution (95% O2/5% CO2) containing 5.5 mmol/l glucose (8). They were then
incubated in media containing 0, 5.5, or 25 mmol/l glucose and different
concentations of leucine (0–200 mol/l) for varying time periods as indicated
in the Fig. legends. (Physiological concentration of leucine is usually 70–120
mol/l) [9,10].) At the end of the incubation, muscles were blotted, quick-
frozen in liquid nitrogen, and stored at 80°C until they were used for
analyses.
AMPK activity assay. AMPK activity was measured in the EDL as described
previously (8,11). In brief, frozen muscle was homogenized (20 mmol/l Tris,
pH 7.4, 5 mmol/l EDTA, 10 mmol/l Na4P2O7, 100 mmol/l NaF, 2 mmol/l Na3VO4,
1% NP-40, 1 mmol/l phenylmethanesulfonyl ﬂuoride (PMSF), 0.006 mg/ml
aprotinin, and 0.006 mg/ml leupeptin), and the muscle lysate containing
200-g protein was immunoprecipitated with speciﬁc antibodies to the -2 or
-1 catalytic subunit of AMPK (11) and protein A/G agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA). Beads were washed ﬁve times, and the
immobilized enzyme was assayed based on the phosphorylation of SAMS
peptide (0.2 mmol/l) by 0.2 mmol/l ATP (containing 2 Ci [-
32P] ATP) in the
presence and absence of 0.2 mmol/l AMP. Label incorporation into the SAMS
peptide was measured on a Racbeta 1214 scintillation counter.
Western blot analysis. Protein homogenates (50 g) were run on a SDS
polyacrylamide gel (4–15% gradient; BioRad) and transferred onto a polyvi-
nylidene ﬂuoride membrane (Bio-Rad). Membranes were then stained with
Ponceau S (1% in 5% acetic acid) to ensure even transfer and blocked in
Tris-buffered saline (pH 7.5) containing 0.05% Tween-20 and 5% milk for1ha t
room temperature. After this, they were incubated overnight in primary
antibodies (P-AMPK, P-ACC, total AMPK, P-mTOR, P-p70S6K, P-raptor, and
P-TSC2) at a 1:1,000 dilution. They were then incubated with a secondary
antibody conjugated to horseradish peroxidase (Amersham) at a 1:5,000
dilution and subjected to an enhanced chemiluminescence solution (Pierce).
Densitometry was performed using Scion Image software (8).
Assessment of protein synthesis. EDL were initially equilibrated in Krebs-
Henseleit solution containing 5.5 mmol/l glucose for 20 min. They were then
incubated for1hi nfresh medium containing 2 mCi/ml of
14C-phenylalanine,
unlabeled phenylalanine at a ﬁnal concentration of 100 mol/l/ml, and the
indicated concentrations of glucose and leucine. At the end of the incubation,
muscles were blotted and homogenized in 10% tricarboxlylic acid (TCA).
Samples were centrifuged at 10,000g for 10 min at 4°C, and TCA-insoluble
material was washed three times with 10% TCA. The resultant pellet was
solubilized in 0.1 N NaOH at 37°C for 2 h and used for determination of protein
abundance and phenylalanine incorporated into muscle protein (7). Protein
mass was determined by the bicinchoninic acid procedure (see below) and
protein-associated radioactivity by liquid scintillation counting. Protein syn-
thesis was calculated by dividing the protein-bound radioactivity by the
speciﬁc activity of free leucine in the incubation medium. The results are
expressed as nanomoles of leucine incorporated per milligram protein per
hour.
Glucose infusion. Glucose infusion was carried out as described previously
(12). Brieﬂy, 7 days after cannulation surgery, rats were randomly divided into
treatment groups. After a basal blood sample (600 l) was taken, a 50%
(wt/vol) glucose solution was infused for either 0 or 5 h using a peristaltic
roller pump (101U/R; Watson-Marlow, Falmouth, U.K.). Blood samples were
taken every 30 min, and the glucose infusion rate was altered to maintain a
blood glucose concentration of 11 mmol/l (16–17 mmol/l plasma glucose).
Other analyses. Protein concentrations were determined with the bicincho-
ninic acid reagent (Pierce, Rockford, IL) using bovine serum albumin (BSA) as
the standard. ATP, AMP, ADP, and phosphocreatine were measured spectro-
photometrically as previously described (8). Malonyl CoA was determined
radioenzymatically using the method of McGarry et al. (13), though slightly
modiﬁed. Lactate and pyruvate was determined spectrophotometrically using
lactate dehydrogenase and NAD (8,14).
Statistics. Results are expressed as means  SEM. Statistical differences
between two groups were determined by Student t test where multiple groups
were compared by ANOVA followed by Student-Newman-Keuls post hoc
analysis. Differences between groups were considered statistically signiﬁcant
at P  0.05.
RESULTS
Incubation with leucine increases protein synthesis
and the phosphorylation of mTOR, p70S6K, and
4EBP1. In keeping with previous reports in muscle (15)
and pancreatic -cells (16), incubation of the EDL with
leucine (100 and 200 mol/l) for 1 h signiﬁcantly increased
protein synthesis (Fig. 1A), an effect associated temporally
with increases in the phosphorylation of mTOR and
p70S6K but not another mTOR target, 4EBP1 (Fig. 1B and
C). Twenty percent increases in both mTOR and p70S6K
phosphorylation were found in the presence of 100
mol/l isoleucine; however, neither achieved statistical
signiﬁcance (Fig. S1, available in an online appendix
[http://diabetes.diabetesjournals.org/cgi/content/full/
db09-1870/DC1]).
Leucine concurrently diminishes AMPK phosphoryla-
tion and activity. EDL incubated with leucine for 1 h also
demonstrated a signiﬁcant decrease in the phosphoryla-
tion of AMPK at Thr172. As shown in Fig. 2A, a progressive
decrease in the abundance of both P-AMPK and its down-
stream target acetyl CoA carboxylase (ACC) occurred as
the concentration of leucine in the medium was increased
from 0 to 50, 100, and 200 mol/l. An almost identical
pattern was observed when the activity of the 2 isoform
of AMPK was measured (Fig. 2B). In contrast, the activity
of 1 AMPK was unchanged (data not shown). Time
course studies revealed that 100 mol/l leucine decreased
AMPK phosphorylation by 20% at 15 min, 40% by 30 min,
and 80% after 2 h (Fig. 2C). Incubation with 100 mol/l
isoleucine, another branched chain amino acid, also de-
creased AMPK activity, although not to the same extent as
leucine. In contrast, incubation with 100 mol/l glutamine
had no effect (Fig. 2D).
Incubation with glucose mimics the effects of leucine
on protein synthesis, mTOR/p70S6K phosphoryla-
tion, and AMPK phosphorylation and activity. Incuba-
tion with glucose had effects very similar to those of
leucine. As shown in Fig. 3A, protein synthesis increased
by more than twofold when the medium concentration of
glucose was increased from 5.5 to 25 mmol/l, as did the
phosphorylation of mTOR and p70S6K. Conversely, elimi-
nating glucose from the medium decreased all of these
parameters (Fig. 3B). As with leucine, no change in the
phosphorylation of 4EBP1 was observed.
Incubation of the EDL with higher concentrations of
glucose (25 vs. 5.5 vs. 0 mmol/l) for 1 h also decreased the
phosphorylation of AMPK and ACC (Fig. 4) and the
activity of the 2 isoform of AMPK (data not shown). In
contrast, eliminating glucose from the medium increased
all of these parameters. No change in the activity of 1
AMPK was observed under these conditions (data not
shown). The concentration of malonyl CoA changed in-
versely with the activity and phosphorylation of AMPK as
previously described (11).
AICAR and another AMPK activator, -lipoic acid,
inhibit glucose-induced changes in protein synthesis
and AMPK and mTOR/p70S6K phosphorylation. The
above-mentioned results indicate that the ability of both
leucine and glucose to increase mTOR signaling and
protein synthesis is associated with a decrease in AMPK
A.K. SAHA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2427phosphorylation and 2-AMPK activity. To assess whether
AMPK downregulation might be the cause of these
changes, studies were performed in which AMPK down-
regulation was prevented by coincubation with the AMPK
activators, AICAR, or -lipoic acid (ALA). In muscles
incubated with 5.5 mmol/l glucose for 1 h, AICAR (1
mmol/l) decreased protein synthesis by 50% to a rate
similar to that observed in muscles incubated in a glucose-
free medium (Fig. 5A). As shown in Fig. 5B, AICAR
activated 2-AMPK but not 1-AMPK and it increased the
phosphorylation of AMPK and ACC and decreased the
concentration of malonyl CoA (Fig. 5C). In addition, it
diminished the phosphorylation of both mTOR and
p70S6K (Fig. 5D).
Almost identical ﬁndings were observed when the EDL
was incubated with ALA, a naturally occurring short-chain
fatty acid that has been shown to activate AMPK in muscle
by increasing Ca
2	/calmodulin-dependent protein kinase
kinase (CAMKK) (17). Thus, at 5 mmol/l glucose, incu-
bation with 100 mol/l ALA increased the phosphorylation
of AMPK by threefold (Fig. S2A) and decreased both
mTOR phosphorylation (Fig. S2B) and protein synthesis
by 50% (Fig. S2C). As shown below in Fig. 7, AICAR
prevented the inhibition of insulin-stimulated protein ki-
nase B (PKB)/Akt phosphorylation caused by high glucose
and leucine. To determine whether this effect is not
speciﬁc to AICAR, we treated EDL muscle with ALA in the
presence of high glucose. As shown in the Fig. S2D, the
decrease in Akt phosphorylation by high glucose was
completely prevented by ALA.
Effects of AICAR on mTOR phosphorylation and
protein synthesis in EDL incubated with 25 mmol/l
glucose or leucine. As shown in Fig. 6A, AICAR pre-
vented, although not completely, the decreases in AMPK
phosphorylation and the increases in mTOR phosphoryla-
tion (Fig. 6B) and protein synthesis (Fig. 6C) caused by
incubating muscle with 25 vs. 5 mmol/l glucose. It also
prevented the changes in these paramaters caused by
incubation with leucine. (Fig. 6D).
AMPK activation also diminishes leucine- and glucose-
induced insulin resistance. Incubation with leucine has
been shown to cause insulin resistance in skeletal muscle
(15). In keeping with this observation, we found that the
ability of insulin to increase the phosphorylation of Akt on
Ser 473 was diminished by 50% in EDL incubated with
leucine at a concentration of 100 mol/l. As shown in Fig.
7, this effect of leucine was completely prevented by
coincubation with 1 mmol/l AICAR. An identical observa-
tion was observed when EDL was incubated with 25
mmol/l glucose and AICAR prevented the decrease in
AMPK phosphoryation caused by high glucose (data not
shown).
Effect of compound C on AMPK and mTOR phosphor-
ylation at 5 mmol/l glucose. The studies with AICAR and
ALA suggest that AMPK activation prevents or partially
prevents both the decrease in AMPK activity and the
increase in mTOR/p70S6K phosphorylation and protein
synthesis caused by leucine and glucose. To assess further
whether decreased AMPK plays a causal role in mediating
these changes, we next evaluated whether the effects of
glucose and leucine on these parameters could be mim-
icked by incubating the EDL with 50 mol/l compound C,
a selective AMPK inhibitor. As shown in Table S1 in the
online appendix, compound C did not affect P-AMPK or
mTOR phosphorylation and protein synthesis under base-
line conditions indicating it could not be used for this
purpose.
Examination of factors that could mediate the down-
regulation of AMPK by leucine and high glucose
Energy state and lactate and pyruvate concentra-
tion. In a search for factors responsible for the decrease in
AMPK phosphorylation caused by leucine and glucose, we
ﬁrst assessed cellular energy state. Incubation with 100
mol/l leucine for 30 min (not shown) or 1 h did not have
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FIG. 1. Effect of incubation with different concentrations of leucine on protein synthesis and P-mTOR, P-p70S6K, and P-4EBP1 phosphorylation.
EDL muscles were incubated in Krebs-Henseleit solution containing 0, 100, and 200 mol/l leucine for 1 h. Protein synthesis was determined at
the end of the incubation on the basis of phenylalanine incorporation into protein (A) and the phosphorylation of mTOR (C, left panel), p70S6K
(C, center panel), and 4EBP1 (C, right panel) by immunoblot analysis. Representative Western blots (B) and densitometric analysis (C). Results
are means  SE (n  6). *P < 0.05 relative to no leucine or time 0. (A high-quality color representation of this ﬁgure is available in the online
issue.)
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(CrP), ATP, ADP, or AMP (Table 1); however, it increased
muscle lactate and, to a lesser extent, pyruvate. The net
result was a nearly twofold increase in the lactate/pyru-
vate ratio (Table 2). In keeping with our previous report
(8), there were not any differences observed in the whole-
tissue concentrations of CrP, ATP, ADP, or AMP in mus-
cles incubated with 25 vs. 5 mmol/l glucose for 1 h, and
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FIG. 2. Dose response and time course of the effects of leucine on AMPK phosphorylation and activity. EDL muscles were incubated in the absence (0)
or presence (50, 100, or 200 mol/l) of leucine for 1 h and muscle lysates analyzed for the phosphorylation of AMPK and its downstream target P-ACC
using SDS-PAGE (A) and for 2-AMPK activity (B). C: The time course (15–120 min) of changes in the abundance of P-AMPK in muscles incubated with
100 mol/l leucine. D: Comparison of effects of leucine, isoleucine, and glutamine (100 mol/l) on total AMPK and P-AMPK. Results are means  SE
(n  6). *P < 0.05 relative to 0 mol/l leucine or time 0. (A high-quality color representation of this ﬁgure is available in the online issue.)
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A.K. SAHA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2429here, too, tissue lactate and pyruvate were increased, as
was the lactate-to-pyruvate ratio (Table 2).
The observed changes in the lactate-to-pyruvate ratio
suggests that leucine and high glucose both cause in-
creases in NADH relative to NAD
	 in muscle. For this
reason, we examined the effects of incubation with glu-
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content. EDL muscles were incubated for1hi nmedia containing 0, 5.5, or 25 mmol/l glucose. Representative Western blots (upper panel).
Densitometric analysis of blots and malonyl CoA content (lower panel). Results are means  SE (n  4). *P < 0.05 vs. 0 mmol/l glucose and **P <
0.01 vs. 0 and 5.5 mmol/l glucose. (A high-quality color representation of this ﬁgure is available in the online issue.)
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	-dependent,
redox-sensitive histone protein deacetylase SIRT1. In a
previous study in HepG2 cells (18), we found that incuba-
tion with 25 vs. 5 mmol/l glucose caused similar changes in
cell lactate and signiﬁcantly diminished SIRT1 abundance
(by 20%). In the present study, SIRT1 protein was also
decreased by 20% in the muscle incubated with 25 vs. 5.5
glucose; however, the decrease was not statistically signif-
icant (P  0.12) (Fig. S4).
Downregulation of mTOR/p70S6K signaling by
rapamycin. We next assessed whether the decrease in
AMPK phosphorylation caused by leucine was dependent
on its ability to activate mTOR. Toward this end, EDL was
incubated with 200 mol/l leucine in the presence or
absence of rapamycin, an inhibitor of mTOR signaling. As
shown in Fig. S3, rapamycin inhibited the increased phos-
phorylation of mTOR and p70S6K induced by leucine;
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FIG. 7. AICAR prevents the inhibition of insulin-stimulated PKB/Akt phos-
phorylation caused by leucine. EDL muscles were preincubated with 100
mol/l leucine for 30 min and then AICAR for 1 h. They were then incubated
with insulin (10 mU/ml) for 10 min. Muscle lysates were analyzed for
PKB/Akt using SDS-PAGE and quantiﬁed as described in RESEARCH DESIGN AND
METHODS. Results are means  SE (n  6). *P < 0.05 vs. basal. **P < 0.01 vs.
insulin. #P < 0.01 vs. insulin plus leucine. (A high-quality color representa-
tion of this ﬁgure is available in the online issue.)
TABLE 1
Effects of leucine and high glucose on adenine nucleotide
ATP AMP ADP CrP
Control (5 mm
glucose) 3.9  0.01 0.04  0.001 0.5  0.03 13  2
Leucine
(100 mol/l) 3.8  0.01 0.035  0.001 0.4  0.02 14.5  4
Glucose
(25 mmol/l) 4.2  0.2 0.045  0.002 0.6  0.03 14  1
Data are means  SE. Nucleotide values were expressed as milli-
moles per gram muscle.
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phorylation caused by leucine (Fig. S2).
Phosphorylation of raptor and TSC2 in EDL muscle
treated with AICAR, high glucose, and leucine. Re-
cently, AICAR-induced activation in myocytes and other
cells has been reported to impair target of rapamycin
complex 1 (TORC1) kinase activity by increasing the
phosphorylation of raptor on Ser 792 (19). As shown in
Fig. S5A, Ser 792 phosphorylation of raptor in EDL incu-
bated with 1 mmol/l AICAR was threefold higher than in
the control group. In contrast, high glucose and leucine at
concentrations that diminished AMPK phosphorylation
and activity did not decrease raptor phosphorylation or
diminish the increase in raptor phosphorylation caused by
AICAR (Fig. S5B).
A second mechanism by which AMPK might diminish
TORC1 signaling and protein synthesis is phosphorylation
of TSC2 on Ser 1387 (20). In the incubated EDL, AICAR
increased TSC2 phosphorylation by fourfold under basal
conditions and two- to threefold in the presence of high
glucose and leucine. However, neither high glucose nor
leucine by themselves diminished TSC2 phosphorylation
from control values (Fig. S6).
Effects of glucose infusion in vivo. To determine
whether the effects of glucose observed in the incubated
EDL also occur in vivo, rats were infused with 50% glucose
for 5 h with the rate of infusion adjusted to maintain
the plasma glucose concentration at 16–17 mmol/l. The
plasma insulin concentration was 250 U/l during the
infusion versus 50 U/l prior to its start. As shown in Fig.
8, AMPK 2 activity in red gastrocnemius muscle de-
creased after5ho fglucose infusion compared with
baseline values, and the phosphorylation of mTOR and
p70S6K increased. It has previously been demonstrated
that the glucose infusion also caused insulin resistance by
5 h (12).
DISCUSSION
The physiological and biochemical relevance of AMPK
activation has been well described (21–24). In contrast,
less is known about the consequences of AMPK downregu-
lation. In the present study, we show that excesses of
glucose and the branched-chain amino acid leucine stim-
ulated protein synthesis and cause insulin resistance in
skeletal muscle and that both effects were paralleled by
decreases in AMPK activity. Furthermore, activation of
AMPK with both AICAR and ALA prevented these events
from occurring.
That leucine at physiological concentrations (70–120
mol/l) stimulates protein synthesis (25,26) and causes
insulin resistance (27) in skeletal muscle and that it does
so by increasing mTOR/p70S6K signaling (28) has been
reported previously. The novel ﬁndings of the present
study are that these changes are associated with a de-
crease in AMPK activity and that they are prevented by
incubation with two AMPK activators that work by differ-
ent mechanisms. Similar observations have recently been
made in the pancreatic -cell (16) suggesting that a
decrease in AMPK activity might also contribute to the
well-documented stimulation of insulin synthesis and se-
cretion by branched-chain amino acids. The results also
indicate that these effects are not unique to leucine, given
that incubation of the EDL with progressively higher
concentrations of glucose produced an almost identical
pattern of events. Collectively, these ﬁndings suggest the
existence of a common fuel sensing and signaling mecha-
nism by which leucine and glucose downregulate AMPK
and alter protein synthesis, insulin sensitivity, and presum-
ably other processes as their concentration is increased
(Fig. S7).
The question of whether the decreased AMPK activity
induced by leucine and glucose mediated their effects on
mTOR/p70S6K signaling and, secondarily, protein synthe-
sis is unresolved. On the one hand, increased AMPK
activity has been shown to inhibit protein synthesis both
by phosphorylating and activating TSC2 and raptor
(19,20)—ﬁndings that we conﬁrmed in the incubated EDL.
Likewise, the decrease in AMPK activity correlated very
strongly with the increases in both protein synthesis and
mTOR/p70S6K signaling. On the other hand, if decreased
AMPK modulated these effects, one would predict that
phosphorylation of the AMPK-sensitive sites on TSC2 and
raptor would be diminished. This was not found. Incuba-
tion with high glucose and leucine failed to decrease both
the phosphorylation of raptor on Ser 792 and TSC2 on Ser
TABLE 2
Effects of leucine and high glucose on lactate and pyruvate
Lactate Pyruvate
Lactate/
pyruvate ratio
Control (5 mmol/l glucose) 12  2 1.1  0.1 11  2
Leucine (100 mol/l) 29  4* 1.4  0.1* 21  3*
Glucose (25 mmol/l) 30  2* 1.7  0.2* 18  1.5*
Data are means  SE (n 
 5–6). Lactate and pyruvate are expressed
as micromoles per milligram muscle. *Signiﬁcantly different from
control at 5 mmol/l glucose (P  0.05).
Basal 5 h Basal 5 h Basal 5 h
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FIG. 8. AMPK 2 activity and phosphorylation of mTOR and p70S6K following glucose infusion. Red gastrocnemius muscle was frozen in liquid
nitrogen after 0 or5ho fglucose infusion, and 2-AMPK activity and phosphorylation of mTOR and p70S6K were determined as described in
RESEARCH DESIGN AND METHODS. Results are means  SE (n  4–6 rats per group). *P < 0.05 vs. basal.
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cules was very low the possibility that a signiﬁcant de-
crease was missed cannot be excluded. Likewise, it is
possible that the decrease in AMPK caused by leucine and
glucose altered other molecules that could upregulate
mTOR/p70S6K (rev. in 20). Clearly, the role of decreased
AMPK in mediating the increase in protein synthesis
caused by these molecules will require further study.
The ﬁndings also raise the following question: by what
mechanism does an excess of two different fuels lead to a
decrease in AMPK activity? The decreases in AMPK activ-
ity induced by both leucine and glucose were not associ-
ated with an increase in energy state; indeed, the whole
tissue concentrations of creatine-P and the AMP-to-ATP
ratio were the same at all glucose and leucine concentra-
tions tested. That a local decrease in the AMP-to-ATP ratio
occurred that was not reﬂected in the whole tissue cannot
be ruled out, however. Perhaps relevant to this discussion,
we found two- to threefold increases in the lactate-to-
pyruvate ratio in muscle incubated with both high glucose
and leucine (Table 2), indicating increases in the cytosolic
state and, presumably, the nuclear redox state (i.e., a
decreased NAD
	-to-NADH ratio). This in turn was associ-
ated with a 20% decrease in the abundance of the NAD
	-
dependent histone/protein deacetylase SIRT1, an enzyme
reported to deacetylate the AMPK kinase liver kinase B 1,
leading to an increase in its activity and that of AMPK
(29–31). On the other hand, the decrease in SIRT1 abun-
dance observed here was not statistically signiﬁcant (P 
0.12; n 
 6). This contrasts with an earlier study, in which
we incubated HepG2 cells in a high-glucose medium (25
vs. 5 mmol/l) and observed similar decreases in AMPK
phosphorylation and SIRT1 abundance (20%)—both of
which were statistically signiﬁcant (18). Clearly, further
investigations are needed to assess whether glucose and
leucine affect SIRT1 in the EDL. Finally, incubation of the
EDL with the mTOR inhibitor, rapamycin, had no effect on
the ability of leucine to diminish AMPK phosphorylation
(Fig. S3). Thus, the decrease in AMPK activity was not a
consequence of mTOR activation.
With respect to the relevance of the ﬁndings to muscle in
vivo, the infusion of glucose at a rate sufﬁcient to increase its
plasma concentration to 16–17 mmol/l and plasma insulin
levels from 50 to 250 mU/ml increased both mTOR/p70S6K
signaling and decreased AMPK activity after 5 h (Fig. 8).
Others have shown that feeding a high-protein diet (ingestion
of branched-chain amino acids) causes similar changes in
AMPK and mTOR/p70S6K in liver (32). Presumably, these
events occur in muscle and liver physiologically after meals
dependent on their composition. Whether the glucose- and
leucine-induced decreases in AMPK activity contribute to the
postprandial increases in protein (mTOR/p70S6K) synthesis
is open to debate—as it is in the incubated EDL. On the other
hand, it is highly likely that concurrent changes in lipid
synthesis in muscle during a glucose infusion (12) are due to
the decrease in AMPK because they are associated with
decreased phosphorylation and increased activity of the
AMPK target ACC. Also, in keeping with this conclusion,
in the present study we found that the concentration of
the ACC product malonyl CoA was elevated in the EDL
when it was incubated with leucine or high glucose
(Figs. 4 and 5).
As already noted, incubation of muscles with elevated
concentrations of leucine (27) or glucose (8) have been
shown to cause insulin resistance. The results presented
here suggest that the insulin resistance correlates with a
decrease in AMPK activity; however, for the same reason
discussed in the context of mTOR/p70S6K signaling and
protein synthesis, it is unclear whether the decrease in
AMPK was a causal event. Whatever the mechanism, we
would propose that such fuel-induced insulin resistance in
vivo develops postprandially when the muscle or liver cell
senses its need to synthesize glycogen or protein has been
met and that it is to the beneﬁt of the organism to shunt
glucose and amino acids to other tissues (e.g., adipose
tissue) for storage. By virtue of the setting in which it
occurs, and its likely reversibility, one might refer to this
phenomenon as “physiological insulin resistance.”
Whether a more sustained decrease in AMPK activity
caused by glucose and leucine can lead to pathological
insulin resistance (i.e., insulin-resistance associated with
less reversible cellular abnormalities) in vivo remains to
be determined. In keeping with such a notion, the insulin
resistance caused by exposure of cultured endothelial
cells to a high-glucose medium for 24 h is associated with
mitochondrial dysfunction, apoptosis, oxidative stress,
and inﬂammation (33–35), all of which are prevented by
AMPK activation. The early observation that amino acid
levels are elevated in the plasma of obese individuals
(36,37) ﬁrst raised the possibility that they may be in-
volved in the development of obesity-linked or diet-in-
duced insulin resistance. Subsequently, infusion of the
branched-chain amino acid leucine was found to impair
glucose uptake in humans despite elevated plasma insulin
levels (38), and in rodents fed a high-fat diet, branched-
chain amino acids have been implicated in the develop-
ment of obesity-associated insulin resistance (39).
Whether decreases in AMPK activity or an impairment of
its activation occurred in these settings was not examined.
Finally, decreased AMPK activity has been observed in
many rodents with chronic insulin resistance including
ob/ob mice (40), fa/fa and ZDF rats (41,42), and the IL-6 KO
mouse (43). However, in all of these rodents it was
attributable to a genetic lack of a hormone or its receptor.
In summary, we have demonstrated that incubation of
rat skeletal muscle with moderately elevated concentra-
tions of leucine or glucose suppresses AMPK activation
and concomitantly increases mTOR/p70S6K signaling and
protein synthesis and leads to insulin resistance. All of
these changes were associated with a decrease in AMPK
activity and were prevented by incubating the muscles
with the AMPK activators AICAR or -lipoic acid. Al-
though collectively these ﬁndings suggest that a decrease
in AMPK activity mediates the effects of high glucose and
leucine, direct evidence for this is still lacking.
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